{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"53.7","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from randomization to disease progression or death from any cause, whichever occurred first. Disease progression is defined using the ECOG Myeloma Response Criteria. Kaplan-Meier method is used to estimate the 1-year progression-free survival probability. 42 eligible and treated patients were included in the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction treatment: PS-341 1.3 mg/m2 IV push days 1, 4, 8, and 11. As per the PS-341 package insert, there should be at least 72 hours between each PS-341 dose. Repeat cycles every 3 weeks for a total of 8 cycles.\n\nMaintenance treatment: PS-341 1.3 mg/m2 IV push days 1 and 15\n\nReinduction treatment: PS-341 1.3 mg/m2 IV push days 1, 4, 8, and 11. As per the PS-341 package insert, there should be at least 72 hours between each PS-341 dose.","id":"OG000","title":"PS-341"}],"paramType":"NUMBER","populationDescription":"42 eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Every 3 months if patient is <2 years from study entry, every 6 months if patient is 2-6 years from study entry, no specific requirment if patient is more than 6 years from study entry","title":"1-year Progression Free Survival Probability","type":"SECONDARY","unitOfMeasure":"percentage of participants"}